Monoclonal antibody ICR-62

Drug Profile

Monoclonal antibody ICR-62

Latest Information Update: 26 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Royal Marsden Hospital; The Institute of Cancer Research
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 Sep 1998 A preclinical study has been added to the pharmacodynamics section
  • 08 Mar 1996 A study has been added to the therapeutic trials and adverse events sections
  • 17 Jan 1995 Phase-I clinical trials for Cancer in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top